Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This is a phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics, and
anti-tumor activity of AK119 and AK112 With or Without Chemotherapy for NSCLC patients.